access to specialized medical care. PSA assays were introduced in 1991. The East Anglian Registry receives notification of the deaths of all individuals flagged as having cancer or where cancer is mentioned on the death certificate, from the Office of National Statistics. In addition, it actively follows up its patients 3 years after diagnosis and then every 5 years until death, ensuring almost complete follow-up. Mortality data were obtained from Statistics Netherlands and the British Office of National Statistics. The midyear population estimates were used for each individual year included in the study.
Analysis
The incidence rates per 100 000 person-years for the age band 40-59 were standardized to the European Standard Population using 5-year age-specific rates for 5-year calendar periods. As the median survival time is approximately 5 years, we calculated the age-standardized mortality rates for the age band 45-64 years. Poisson regression analysis was applied to model incidence and mortality (Clayton and Hills, 1993) , using the GENMOD procedure of the statistical package SAS. Significance of terms in the models was tested with the likelihood-ratio test (Clayton and Hills, 1993) . Crude and relative survival rates were calculated using the actuarial (life table) method. Relative survival is the ratio of the crude to the expected survival (Ederer et al, 1961) . The expected survival was calculated from life tables derived from regional mortality statistics; data were compiled into 5-year age groups and calendar year. A software package from the Finnish Cancer Registry (Hakulinen and Abeywickrama, 1985) was used to calculate the survival rates. The rates were adjusted for the changing age distribution of the patient groups during the course of the follow-up (Ederer II option) . Cases identified at death were excluded from the analyses. We used grade information as it was registered, that is scored according to the classification of malignant tumours (UICC, 1992) . Information about stage was available only in the Eindhoven Cancer Registry and only from 1980. Based on clinical TNM assessment (UICC, 1992), we classified stages in three categories: small tumours confined to the prostate (T1-T2) without evidence of metastases were classified as localized; tumours that invaded surrounding structures (T3-T4) but without evidence of metastases were classified as locally advanced; patients with distant or lymph node metastases were classified as metastasized. Grade and stage, both available from 1980, are presented both with and without inclusion of the unknown cases. Differences in proportions were tested with the chi-square test (excluding unknown cases).
We classified initial treatment as TURP (including patients detected incidentally because of TURP), hormonal treatment, hormonal treatment after TURP and radiotherapy. Patients receiving radiotherapy after TURP or radiotherapy and hormonal therapy were included in the radiotherapy group. Treatment information was available for the period 1971-89 in the Eindhoven Registry and from 1980 to 1989 in East Anglia.
RESULTS
The number of patients aged 40-59 diagnosed with prostate cancer between 1971 and 1989 was 181 in south-east Netherlands and 384 in East Anglia, being 7% and 4% respectively of patients at all ages with prostate cancer diagnosed between 1971 and 1989. The proportion of patients with a histologically confirmed diagnosis at ages 40-59 was more than 95% during the whole study period in both populations.
Between 1971 and 1989, the age-adjusted incidence rate for men aged 40-59 increased from 8.8 per 10 5 to 12.5 per 10 5 in south-east Netherlands and from 7.0 per 10 5 to 11.6 per 10 5 in East Anglia (Figure 1 ). The mean age at diagnosis of the patients in this age group barely changed over the study period, being 55.4 years in The Netherlands and 55.6 in East Anglia. A multivariate model for the incidence up to 1994 was fitted that included age group, registry and calendar period [deviance 35.0, 34 degrees of freedom (d.f.)]. The risk ratio of the incidence increased for each subsequent period up to 1990-94 (Table 1 ). The test for trend was significant (P = 0.0001) and the trend was similar in both registries. A similar result was obtained when the period 1990-94 was excluded. The age-standardized mortality rate for prostate cancer among men aged 45-64 years increased between 1971 and 1989 from 7.4 to 11.1 per 10 5 in south-east Netherlands and from 7.5 to 12.1 per 10 5 in East Anglia. A model was built including age group, calendar period and registry (deviance 47.1, 34 d.f.). The risk ratio increased with each subsequent period up to 1985-89, followed by a slight decline in 1990-94 (Table 1) . Nevertheless, the test for trend was significant (P = 0.0001) and the trend was similar in both registries. In south-east Netherlands, 5-year relative survival improved slightly in the early 1970s, but declined from 65% (95% CI 47-83) in 1975-79 to 48% (CI 34-62) in 1985-89 (Figure 1) . In East Anglia, 5-year relative survival was initially considerably lower, being 48% (CI 34-62) in 1971-74 and decreasing slightly to 46% (CI 36-56) in 1985-89. The crude survival followed a similar trend.
In spite of an increase in the estimated proportion of patients with localized cancer from 47% in 1980-84 to 56% in 1985-89 in south-east Netherlands (Table 2 ), the estimated proportion of patients with poorly differentiated tumours increased from 15% to 25% (Table 3 ). The proportion of patients aged 40-59 years receiving radiotherapy increased from 21% in 1975-79 to 55% in 1985-89 in south-east Netherlands and radiotherapy has also been the main treatment modality in East Anglia between 1980 and 1989 ( Table 4 ). The remainder of patients received endocrine therapy or TURP. Radical prostatectomy was only rarely applied before 1990 in both populations.
DISCUSSION
We report a similar rise in the incidence of prostate cancer among men aged 40-59 years in south-east Netherlands and East Anglia and no improvement in prognosis in the period preceding the introduction of PSA testing in 1990. Improved diagnosis does not seem to be an important factor in the rise in incidence because it would have resulted in the inclusion of more non-aggressive cases and, thus, in improved survival. Moreover, in spite of a more favourable stage distribution, we did not observe an increase in well-differentiated tumours in this period.
Our findings are conditional on the accuracy of the two cancer registries. Comparisons with mortality data and analysis of referral patterns indicate that both registries can be considered virtually complete for prostate cancer as of 1971 and both comply with the standards of the International Agency for Research on Cancer (Parkin et al, 1992) . Few patients were lost to follow-up, so that selective loss is not likely to be an issue. The study populations were relatively small, especially in south-east Netherlands, but our (Helgesen et al, 1996) . In Scotland, it declined from 47% in 1978 -82 to 32% in 1983 -87 (Black et al, 1993 . In Switzerland (Vaud), the relative survival for patients aged under 60 only improved slightly from 39% in 1974 -78 to 41% in 1979 -83 (Levi et al, 1992 , which was similar to the situation for Finnish patients (Dickman et al, 1998 ). We do not know why the prognosis barely changed in East Anglia but deteriorated in southeast Netherlands. A lower level of access to specialized care may have played a role in the initially lower survival in East Anglia, because the Eurocare study showed that similar differences in survival existed between south-east Netherlands and Great Britain for patients with lung, breast or colorectal cancer, which may be related to differences in stage at diagnosis (Berrino et al, 1995) . Increasing awareness of prostate cancer and early diagnosis was probably not apparent before 1980 in East Anglia. Our hypothesis, that a genuine increase in incidence has occurred, is also supported by the increase in mortality attributable to prostate cancer under 65 years, which was similar in both populations, although it was followed by a small decline in 1990-94. An analysis of national mortality data from 1950-89 showed an increase in mortality due to prostate cancer in consecutive birth cohorts of men born around 1925 in The Netherlands ( Van der Gulden et al, 1994) . In Norway, the increase in both incidence and mortality due to prostate cancer between 1957 and 1991 was highest in men under 60 years (Harvei et al, 1996) . In the USA, mortality due to prostate cancer has started to decline since 1991-95, in particular for men under age 75 (Hoeksema and Law, 1996) , whereas it had increased slightly in those under age 65 in the years beforehand (Kosary et al, 1995) . The decline, however, may be related to the widespread introduction of early detection and intervention techniques. Changes in cause-specific mortality such as that observed for cancer of the prostate in Eindhoven and East Anglia should be interpreted with caution. All-cause mortality has also been declining in both populations for the age group studied. In particular, mortality attributable to cardiovascular causes declined in The Netherlands from 499 per 10 5 in 1970 to 301 per 10 5 in 1990 for men aged 45-64 years (Central Bureau of Statistics, 1992) . As a result of the decrease in concurrent causes of death, the probability that prostate cancer was recorded as the cause of death may have increased. However, this explanation would be more plausible for mortality in older age groups.
We suggest, therefore, that an increased risk of prostate cancer in those under age 60 has almost certainly occurred over the period 1971 to 1989. As far as we know, only one aetiological study has focused on the under 60 age group, reporting a relative risk (RR) of 1.9 for cigarette smoking, a RR of 1.4 for vasectomy and a RR of 2.3 for early age at first sexual intercourse (Honda et al, 1988) . Recently, Rodriguez et al (1997) reported a significant association of current smoking with fatal prostate cancer (RR 1.34), which was highest among men below 60 years (RR 1.83), but there was no association with the number of cigarettes smoked or with the duration of smoking at baseline for the cohort in 1982. Nor was there any increased risk for former smokers (Rodriguez et al, 1997) . This, as well as results from other large studies, suggests that smoking may adversely influence survival in prostate cancer patients. Increased occurrence of a factor associated with a worse survival could be an alternative explanation for our findings. However, smoking is not a likely candidate, because the proportion of male smokers decreased markedly from 95% in 1960 to 40% in 1981 in The Netherlands (Janssen-Heijnen et al, 1995) and also in England (Coleman et al, 1993) .
Unfavourable changes in the health care system do not seem to play a role, because the proportion of cases detected at an earlier stage increased over the study period, at least in south-east Netherlands. Furthermore, radiotherapy was applied increasingly during the study period. Although a beneficial effect of radiotherapy on survival has not been proven definitively (Lu-Yao and Yao, 1997), it seems unlikely that radiotherapy has been detrimental for prostate cancer patients. We, therefore, assume that increased incidence of fatal prostate cancer, of which the cause still needs to be unravelled, should explain our findings.
Although the incidence continued to increase, mortality due to prostate cancer decreased slightly in the 1990s. This could mean that the postulated genuine increase in incidence has come to a halt in the 1990s. Continuing studies of incidence and survival may provide more insight into the nature of the most recent increase in incidence.
From the current study, we conclude that increased detection of prostate cancer by TURP cannot explain the considerable increase in incidence between 1971 and 1989 in the age group below 60 years. 
